Entero Therapeutics, Inc.
ENTODrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Porcine PERT
Exocrine Pancreatic Insufficiency (EPI)
adrulipase
Exocrine Pancreatic Insufficiency
MS1819
Exocrine Pancreatic Insufficiency (EPI)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Porcine PERT | Phase 2 | Exocrine Pancreatic Insufficiency (EPI) | - | - |
adrulipase | Phase 2 | Exocrine Pancreatic Insufficiency | - | - |
MS1819 | Phase 2 | Exocrine Pancreatic Insufficiency (EPI) | - | - |
Frequently asked questions
What is in Entero Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Entero Therapeutics, Inc.'s (ENTO) pipeline across Phase 2. Its lead program is Porcine PERT (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Entero Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Entero Therapeutics, Inc. (ENTO) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ENTO biotech catalysts?→
Add ENTO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Entero Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.